Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C

The aim of our study was features the effectiveness of the treatment of moxifloxacin (Mfx) in patients with co-infections TB/HIV and hepatitis B,and/or C. <b>Materials and Methods:</b> Our research included 63 patients with co-infections, newly diagnosed pulmonary TB/HIV with a positive smear sputum, susceptibility MTB to fist-line anti-TB drugs and Mfx with concomitant viral hepatitis B, and/or С. Patients were divided into two groups:the 1st group-30 patients that were administered treatment according to a scheme (MfxHRE)and the 2nd group - 33 patients – a standard therapy (HREZ)during 2 months.All the patients were administered a standard antiretroviral therapy.Treatment of viral hepatitis B and C was not performed during this stage. <b>Results and Discussion:</b> Due to the use of the modified chemotherapy regimen in patients from Group 1, the efficacy of treatment after completing the intensive phase of chemotherapy was significantly higher by stopping clinical symptoms–23(76.7%) and 16(48.5%),p=0.02;culture conversion-20(66.7%) and 13(39.4%),p=0.03;cavity healing in the lungs-19(63.3%) and 11(33.3%),p=0.02 than standard treatment in patients from group2.Quantity of adverse events in anti-TB and antiretroviral drugs was credibly lower in 7(23.3%)patients from group 1 compared to 16(48.5%) group 2,p=0.04. <b>Conclusions:</b> The use of Mfx in of anti-TB treatment in patients with TB/HIV in the intensive phase of therapy allows to achieve a significant decrease in the clinical symptoms, culture conversion, cavity healing in the lungs, reduce the incidence of adverse reactions, which provides continuous treatment compared to patients that are taking standard therapy.